These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 33099434)

  • 1. Future Perspectives.
    Dispenzieri A; Merlini G
    Hematol Oncol Clin North Am; 2020 Dec; 34(6):1205-1214. PubMed ID: 33099434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Staging systems use for risk stratification of systemic amyloidosis in the era of high-sensitivity troponin T assay.
    Muchtar E; Kumar SK; Gertz MA; Grogan M; AbouEzzeddine OF; Jaffe AS; Dispenzieri A
    Blood; 2019 Feb; 133(7):763-766. PubMed ID: 30545829
    [No Abstract]   [Full Text] [Related]  

  • 3. Cutaneous light chain amyloidosis with multiple myeloma: A concise review.
    Andrei M; Wang JC
    Hematol Oncol Stem Cell Ther; 2019 Jun; 12(2):71-81. PubMed ID: 30261180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Light chain amyloidosis: Where are the light chains from and how they play their pathogenic role?
    Zhang C; Huang X; Li J
    Blood Rev; 2017 Jul; 31(4):261-270. PubMed ID: 28336182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes of patients with AL amyloidosis and low serum free light chain levels at diagnosis.
    Nguyen VP; Rosenberg A; Mendelson LM; Comenzo RL; Varga C; Sanchorawala V
    Amyloid; 2018 Sep; 25(3):156-159. PubMed ID: 30032640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [To positively deal with the challenges brought by the diagnosis and treatment of systemic light chain amyloidosis].
    Huang XH; Liu ZH
    Zhonghua Yi Xue Za Zhi; 2021 Jun; 101(22):1631-1634. PubMed ID: 34126710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transcriptional heterogeneity of clonal plasma cells and immune evasion in immunoglobulin light chain amyloidosis.
    Wang Y; Xu L; Liu Y; Hu Y; Shi Q; Jin L; Yang L; Wang P; Zhang K; Huang X; Ge Q; Lu J
    Int J Hematol; 2021 Feb; 113(2):231-242. PubMed ID: 33040275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peripheral Nervous System Involvement.
    Thaisetthawatkul P; Dyck PJB
    Hematol Oncol Clin North Am; 2020 Dec; 34(6):1091-1098. PubMed ID: 33099426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monoclonal Antibody Therapies in Systemic Light-Chain Amyloidosis.
    Godara A; Palladini G
    Hematol Oncol Clin North Am; 2020 Dec; 34(6):1145-1159. PubMed ID: 33099430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Spectrum of Monoclonal Immunoglobulin-Associated Diseases.
    Tuchman SA; Zonder JA
    Hematol Oncol Clin North Am; 2020 Dec; 34(6):997-1008. PubMed ID: 33099435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Options for Chemotherapy and Scoring Response and Relapse.
    Varga C; Chaulagain C
    Hematol Oncol Clin North Am; 2020 Dec; 34(6):1115-1131. PubMed ID: 33099428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic Amyloidosis Due to Clonal Plasma Cell Diseases.
    Bianchi G; Kumar S
    Hematol Oncol Clin North Am; 2020 Dec; 34(6):1009-1026. PubMed ID: 33099420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver and Gastrointestinal Involvement: Update.
    Rosenzweig M; Kastritis E
    Hematol Oncol Clin North Am; 2020 Dec; 34(6S):e1-e13. PubMed ID: 33518015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Supportive Care for Patients with Systemic Light Chain Amyloidosis.
    Wong SW; Fogaren T
    Hematol Oncol Clin North Am; 2020 Dec; 34(6):1177-1191. PubMed ID: 33099432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal Involvement in Systemic Amyloidosis Caused by Monoclonal Immunoglobulins.
    Karam S; Leung N
    Hematol Oncol Clin North Am; 2020 Dec; 34(6):1069-1079. PubMed ID: 33099424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibril-directed Therapies in Systemic Light Chain AL Amyloidosis.
    Bhutani D; Leng S; Lentzsch S
    Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):555-559. PubMed ID: 31262668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnosis and management of systemic light chain AL amyloidosis.
    Bhutani D; Lentzsch S
    Pharmacol Ther; 2020 Oct; 214():107612. PubMed ID: 32562825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic Amyloidosis due to Low-Grade Lymphoma.
    Wechalekar AD; Chakraborty R; Lentzsch S
    Hematol Oncol Clin North Am; 2020 Dec; 34(6):1027-1039. PubMed ID: 33099421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapies for cardiac light chain amyloidosis: An update.
    Aimo A; Buda G; Fontana M; Barison A; Vergaro G; Emdin M; Merlini G
    Int J Cardiol; 2018 Nov; 271():152-160. PubMed ID: 30223349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fundamentals of Light Chain Cardiac Amyloidosis: A Focused Review.
    Latif A; Lateef N; Razzaq F; Kapoor V; Ahsan MJ; Ashfaq M; Iftikhar A; Anwer F; Holmberg M; William P
    Cardiovasc Hematol Disord Drug Targets; 2020; 20(4):274-283. PubMed ID: 33256586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.